Onyx Pharma's (ONXX) Kyprolis Receives FDA Approval as Multiple Myeloma Treatment

Article Stock Quotes (1) Comments (0)

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), received U.S. Food and Drug Administration (FDA) approval for Kyprolis™ (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy. The approval of Kyprolis is based on response rate.

The MMRF’s affiliate organization, the Multiple Myeloma Research Consortium (MMRC), a clinical trials network of 16 leading multiple myeloma centers in North America, has bolstered the clinical development of Kyprolis for the past six years, providing clinical trial support and resources, including driving accrual to the pivotal Phase IIb trial (003-A1) that supported the accelerated approval of the treatment.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
• AMD (AMD) Looks to Outdo Intel (INTC) in Battle of Performance Tablets with Latest SoC Offerings
• Highway Holdings (HIHO) Surges, Halted on $400K Per Year Order

Create E-mail Alert Related Categories

Corporate News, FDA, Trading Halts

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?